B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KDM4B

MOLECULAR TARGET

lysine demethylase 4B

UniProt: O94953NCBI Gene: 230304 compounds

KDM4B (lysine demethylase 4B) is targeted by 4 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KDM4B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvespimycin3.4029
2ciclopirox3.1823
319-((1'S,4'R)-4'-hydroxy-1'-methoxy-2'-oxopentyl)geldanamycin [Supplementary Concept]0.691
4triolimus [Supplementary Concept]0.691

About KDM4B as a Drug Target

KDM4B (lysine demethylase 4B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 4 compounds with documented KDM4B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KDM4B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.